Clinical Review

Pharmacologic management of chronic neuropathic pain

Review of the Canadian Pain Society consensus statement

Alex Mu MD FRCPC  Erica Weinberg MD  Dwight E. Moulin MD PhD  Hance Clarke MD PhD FRCPC

Abstract

Objective To provide family physicians with a practical clinical summary of the Canadian Pain Society (CPS) revised consensus statement on the pharmacologic management of neuropathic pain.

Quality of evidence A multidisciplinary interest group within the CPS conducted a systematic review of the literature on the current treatments of neuropathic pain in drafting the revised consensus statement.

Main message Gabapentinoids, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors are the first-line agents for treating neuropathic pain. Tramadol and other opioids are recommended as second-line agents, while cannabinoids are newly recommended as third-line agents. Other anticonvulsants, methadone, tapentadol, topical lidocaine, and botulinum toxin are recommended as fourth-line agents.

Conclusion Many pharmacologic analgesics exist for the treatment of neuropathic pain. Through evidence-based recommendations, the CPS revised consensus statement helps guide family physicians in the management of patients with neuropathic pain.

EDITOR’S KEY POINTS

• Gabapentinoids and tricyclic antidepressants play an important role in first-line management of neuropathic pain (NeP). Evidence published since the 2007 Canadian Pain Society consensus statement on treatment of NeP shows that serotonin-norepinephrine reuptake inhibitors should now also be among the first-line agents.

• Tramadol and opioids are considered second-line treatments owing to their increased complexity of follow-up and monitoring, plus their potential for adverse side effects, medical complications, and abuse. Cannabinoids are currently recommended as third-line agents, as sufficient-quality studies are currently lacking. Recommended fourth-line treatments include methadone, anticonvulsants with lesser evidence of efficacy (e.g., lamotrigine, lacosamide), tapentadol, and botulinum toxin. There is some support for analgesic combinations in selected NeP conditions.

• Many of these pharmacologic treatments are off-label for pain or on-label for specific pain conditions, and these issues should be clearly conveyed and documented.

POINTS DE REPÈRE DU RÉDACTEUR

• Les gabapentinoïdes et les antidépresseurs tricycliques jouent un rôle important dans la prise en charge de la douleur neuropathique en soins primaires. Des données probantes publiées depuis la déclaration consensuelle de la Société canadienne de la douleur en 2007 sur le traitement de la douleur neuropathique démontrent que les inhibiteurs de la recapture de la sérotonine et de la noradrénaline devraient aussi compter parmi les agents de première intention.

• Le tramadol et les opioïdes sont considérés comme des traitements de deuxième intention en raison de la complexité du suivi et de la surveillance, sans compter leur potentiel d’effets secondaires indésirables, de complications médicales et d’usage abusif. Les cannabinoïdes sont présentement recommandés comme agents de troisième intention, étant donné l’absence actuelle d’études de qualité suffisante. Parmi les traitements de quatrième intention recommandés figurent la méthadone, les anticonvulsivants dont l’efficacité est corroborée par moins de données probantes (p. ex. lamotrigine, lacosamide), le tapentadol et la toxine botulique. Le recours à une combinaison d’analgésiques reçoit un certain appui dans des cas particuliers de douleur neuropathique.

• L’utilisation de bon nombre de ces pharmacothérapies est non indiquée pour la douleur ou encore est indiquée pour des problèmes de douleur spécifiques. Ces faits devraient être clairement communiqués et documentés.

This article has been peer reviewed.

Cet article a fait l’objet d’une révision par des pairs.

Can Fam Physician 2017;63:844-52
Pharmacologic management of chronic neuropathic pain | Clinical Review

de la douleur (SCD) sur la prise en charge pharmacologique de la douleur neuropathique.

**Qualité de l’information** Un groupe d’intérêt multidisciplinaire au sein de la SCD a effectué une revue systématique des ouvrages scientifiques sur les traitements actuels de la douleur neuropathique dans le contexte de la rédaction d’une déclaration consensuelle révisée.

**Message principal** Les gabapentinoïdes, les antidépresseurs tricycliques, et les inhibiteurs de la recapture de la sérotonine et de la noradrénaline sont les agents de première intention pour traiter la douleur neuropathique. Le tramadol et les autres opioides sont recommandés comme agents de deuxième intention, tandis que les cannabinoides sont recommandés depuis peu comme agents de troisième intention. D’autres anticonvulsivants – la méthadone, le tapentadol, la lidocaïne topique et la toxine botulique – sont recommandés comme agents de quatrième intention.

**Conclusion** Il existe de nombreux analgésiques pharmacologiques pour le traitement de la douleur neuropathique. Par ses recommandations fondées sur des données probantes, la déclaration consensuelle révisée de la SCD aide à orienter les médecins de famille dans la prise en charge des patients souffrant de douleur neuropathique.

Neuropathic pain (NeP), caused by a lesion or disease of the somatosensory system, is a common condition seen in the primary care setting. Although the prevalence of NeP is estimated to be 2% to 3% in the developed world, population-based questionnaires estimate that the prevalence could actually be in the range of 4% to 8%. The prevalence of NeP will increase over the next decades as our population ages and experiences more obesity. This has led to increased rates of postherpetic neuralgia and painful diabetic neuropathy. Improved cancer screening and treatments are also leading to more cancer survivors experiencing NeP from various medical and surgical oncologic interventions.

The goals of treatment of NeP, as with other pain conditions, include improvement in function and quality of life, along with the reduction of pain. The ideal treatment of NeP should entail a whole-person approach (biological, psychological, social, spiritual), be multidisciplinary in nature, include prevention or reversal of any underlying cause, and use appropriate pharmacologic and nonpharmacologic therapies. As first-line personnel in the treatment of NeP, primary care clinicians need to be aware of current Canadian guidance on the pharmacologic treatment of NeP so that an appropriate and rational stepwise approach is implemented. The primary aim of this article is to highlight the revised neuropathic pain medication algorithm that was created by a panel of experts within the Canadian Pain Society (CPS).

**Consensus statement development**
The Neuropathic Pain Special Interest Group of the CPS began meeting in 2012 to update the 2007 pharmacologic management guidelines for NeP. This interest group is a multidisciplinary group of individuals with research and clinical expertise relevant to the pathophysiology and management of NeP. Randomized controlled trials (RCTs) and systematic reviews related to the pharmacologic management of NeP from 2007 up to September 2013 were reviewed to develop a revised evidence-based consensus statement.

**Quality of evidence**
As per the published report, MEDLINE and Cochrane databases were used to find systematic reviews, meta-analyses, treatment recommendations, guidelines, and consensus statements published since the first 2007 CPS consensus statement. Studies were excluded if they did not have a control group, had fewer than 10 patients, involved trigeminal or glossopharyngeal neuralgia, or involved cancer NeP, except for well-defined cancer-related postsurgical pain syndromes and chemotherapy-induced NeP. Medications were considered to be first-line if there was high-quality evidence of efficacy (at least 1 class I study or 2 consistent class II studies—level of recommendation grade B or better), if there were positive results in at least 2 NeP models, and if they were considered to be straightforward and of sufficient tolerability to prescribe and monitor. Second- or third-line medications require high-quality evidence of efficacy, but the medications also require more specialized follow-up and monitoring. Fourth-line treatments have at least 1 RCT with positive results, but require further study.

**Main message**
Neuropathic pain is a common condition seen in the family practice setting in Canada. Figure 1 summarizes the revised 2014 CPS consensus statement for pharmacologic management of NeP. Gabapentinoïdes (gabapentin and pregabaline), tricyclic antidepressants (TCAs), and serotonin-norepinephrine reuptake inhibitors (SNRIs) are now recommended as first-line agents. Tramadol and opioids are considered second-line treatments owing to their increased complexity of follow-up and monitoring, plus their potential for adverse side effects, medical complications, and abuse. Cannabinoids are currently recommended as third-line agents, as sufficient-quality studies are currently lacking. Recommended fourth-line treatments include methadone, anticonvulsants with lesser evidence of efficacy (eg, lamotrigine, lacosamide), tapentadol, and botulinum toxin. There is some support for analgesic combinations in selected NeP conditions.
Many of these pharmacologic treatments are off-label for pain or on-label for specific pain conditions, and these issues should be clearly conveyed and documented.

**Assessment and diagnosis of NeP.** Neuropathic pain can be mediated by central causes, such as stroke or multiple sclerosis, and by peripheral causes, such as diabetic neuropathy or surgical procedures. The patient’s history and physical examination findings are essential to diagnosing NeP. Some diagnoses based on history are obvious, such as shingles and diabetes mellitus preceding postherpetic neuralgia and painful diabetic neuropathy, respectively. Questionnaires have been developed to help differentiate between nociceptive pain and NeP. True weakness (different from pain-related or antalgic weakness), reduced or absent reflexes, allodynia, and hyperalgesia all favor a diagnosis of NeP. Often patients describe neuropathic pain as accompanied by sensations of burning, tingling, and electric jolts. Screening tools, such as the Douleur Neuropathique 4, the self-report Leeds Assessment of Neuropathic Symptoms and Signs, and the ID Pain questionnaire (Table 1), have been shown to be valid and reliable discriminators of NeP. Electromyography and nerve conduction studies can provide evidence of nerve injury but might not be sensitive for small-fibre neuropathies. Guidelines are available to determine the diagnostic certainty of NeP.

**CanMEDS–Family Medicine considerations.** Chronic pain conditions, such as NeP, require management by physicians using more than pharmacologic expertise. The CanMEDS–Family Medicine roles described by the College of Family Physicians of Canada serve as a framework for improving patient care. Specifically, as professionals, physicians must commit to regulated, ethical practice with high personal standards of behaviour. Being a scholar requires lifelong commitment to learning, creation, dissemination, and translation of medical pain knowledge. As family medicine experts, the knowledge is applied in a manner that places patients and families in the correct biopsychosocial-spiritual framework within their community. Patients with chronic pain experiencing NeP often describe this condition as severe and unrelenting, and it is often associated with comorbid anxiety and depression. As a communicator, the practitioner should facilitate the doctor-patient relationship through validation of the patient’s pain and communicate the treatment goals, such as improvement of

---

**Table 1. ID Pain questions and scoring: If patients have > 1 painful area, they are to consider the area that is most relevant when answering the ID Pain questions. Scores range from -1 to 5. Higher scores are more indicative of pain with a neuropathic component.**

<table>
<thead>
<tr>
<th>QUESTION</th>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Did the pain feel like pins and needles?</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>2. Did the pain feel hot or burning?</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>3. Did the pain feel numb?</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>4. Did the pain feel like electrical shocks?</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>5. Is the pain made worse with the touch of clothing or bed sheets?</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>6. Is the pain limited to your joints?</td>
<td>-1</td>
<td>0</td>
</tr>
</tbody>
</table>

Adapted from Portenoy.12
sleep, physical functioning, and other elements of quality of life, and discuss pain reduction such that the pain might become “tolerable,” rather than promise the elimination of the pain condition. Patients should be made aware that chronic pain might be a lifelong condition. As a collaborator and leader, treatment goals can be realized by involving multidisciplinary teams (psychologists, physiotherapists, etc) to maximize nonpharmacologic adjunctive treatments. Family physicians serve as their patients’ main advocate within their communities, and help them to navigate the health care system.

**First-line analgesics.** The first-line medications are the gabapentinoid class of anticonvulsants, TCAs, and SNRIs. There are positive results showing efficacy in painful diabetic neuropathy for all first-line analgesics. In the context of postherpetic neuralgia, there has been proof of efficacy for gabapentinoids and TCAs. Pregabalin has additionally been shown to have analgesic benefit in patients with chronic central NeP after spinal cord injury and secondary benefit (improved sleep and reduced anxiety) in central poststroke pain. Tricyclic antidepressants have been shown to relieve pain in various NeP conditions. Of the SNRIs, duloxetine has been found to have analgesic benefit in chemotherapy-induced painful neuropathy, while gabapentin has been shown not to. Additionally, high-dose venlafaxine has shown efficacy in mixed painful polyneuropathy. In the context of idiopathic trigeminal neuralgia, an exception can be made for carbamazepine, which remains the first-choice analgesic. Dosing guidelines for selected NeP analgesia agents can be found in Table 2.

Tricyclic antidepressants are extensively studied, inexpensive, and administered daily. They inhibit the reuptake of serotonin and norepinephrine, block N-methyl-D-aspartate agonist–induced hyperalgesia, and block sodium channels. When prescribing TCAs, secondary amines (nortriptyline, desipramine) are usually better tolerated in terms of sedation, postural hypotension, and anticholinergic effects when compared with tertiary amines (amitriptyline and imipramine) with comparable analgesic efficacy. Side effects might also be reduced by starting at a lower dose, administration in the early evening, and titrating slowly. The analgesic effect of TCAs is independent of the antidepressant effect and the analgesic effect occurs at one-fifth to one-third of the dose required to treat depression. In the geriatric population, TCAs might be deleterious, as they can impair cognition and increase the risk of falls. The updated American Geriatrics Society Beers criteria and version 2 of the STOPP/START (Screening Tool of Older People's Prescriptions and Screening Tool to Alert to Right Treatment) criteria are useful references to minimize inappropriate prescribing in the elderly. As TCAs have been associated with tachycardia and myocardial infarction (at doses above 100 mg daily), the Special Interest Group on Neuropathic Pain (NeuPSIG) recommends a baseline electrocardiogram in patients starting TCAs who are older than 40 years of age and are at risk of sudden cardiac death or who have a history of cardiovascular disease.

Gabapentinoids lead to reduction of the influx of calcium in the terminals of primary afferent neurons entering the dorsal horn of the spinal cord. Gabapentin and pregabalin are not hepatically metabolized, and they do not alter hepatic enzymes. As they are eliminated renally, dose adjustment is required in those with renal insufficiency or those who are undergoing dialysis. Pregabalin can be taken twice a day and has more linear pharmacokinetics relative to gabapentin, which is taken 3 times a day. Somnolence, dizziness, edema, and weight gain are common side effects of gabapentinoids, and they might require low initial dosing and slow titration, especially in the elderly. Serotonin-norepinephrine reuptake inhibitors inhibit the reuptake of serotonin and norepinephrine at neuronal junctions. Duloxetine and venlafaxine are the 2 most studied drugs within this class. A typical side effect of duloxetine and venlafaxine is nausea; other side effects such as elevated heart rate and blood pressure are less common. Gastrointestinal side effects are most common with venlafaxine. Hepatotoxicity has been reported with duloxetine. Duloxetine directly relieves painful physical symptoms, in addition to the pain relief from improved depressive symptoms over time. There is 1 phase III clinical trial of desvenlafaxine in the setting of NeP; at interim analysis, randomization to a 400-mg daily dose was discontinued owing to a clear increase in adverse events. Duloxetine inhibits serotonin to norepinephrine reuptake at a ratio of 9:1 while venlafaxine has a ratio of 30:1. At low doses (<200 mg daily), venlafaxine only inhibits serotonin. There is evidence that combination pharmacotherapy with gabapentinoids and SNRIs can be helpful. Duloxetine should be avoided in those with hepatic insufficiency and severe renal impairment; doses higher than 60 mg daily have not consistently shown benefit in clinical trials. Tricyclic antidepressants, SNRIs, and selective serotonin reuptake inhibitors are all relatively contraindicated with concurrent use of monoamine oxidase inhibitors owing to the possibility of serotonin syndrome.

If patients are appropriately identified as having NeP using standardized NeP tools, first-line medications are very effective early in the treatment process. The quality of the evidence provided above is high for SNRIs and gabapentinoids in the treatment of NeP, but moderate for TCAs if started before opioids. A reduction in pain of 20% to 30% should be considered a success. A change in a patient’s function, sleep pattern, or their ability to be social are key matters of evaluation rather than a pain numeric rating scale score.
### Table 2. Selected neuropathic analgesic dosing regimens

<table>
<thead>
<tr>
<th>AGENT</th>
<th>INITIAL DOSE</th>
<th>TITRATION</th>
<th>DOSE RANGE</th>
<th>ADVERSE EFFECTS</th>
<th>ADDITIONAL INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anticonvulsants</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Gabapentin</td>
<td>100–300 mg/d</td>
<td>Increase by 100–300 mg/d every wk</td>
<td>300–1200 mg 3 times/d</td>
<td>Drowsiness, dizziness, peripheral edema, visual blurring</td>
<td>Dosage adjustments required in renal failure and in elderly patients</td>
</tr>
<tr>
<td>• Pregabalin</td>
<td>25–150 mg/d</td>
<td>Increase by 25–150 mg/d every wk</td>
<td>150–300 mg twice daily</td>
<td>Drowsiness, dizziness, peripheral edema, visual blurring</td>
<td>Similar adjustments in renal failure</td>
</tr>
<tr>
<td>• Carbamazepine</td>
<td>100 mg/d</td>
<td>Increase by 100–200 mg/d every wk</td>
<td>200–400 mg 3 times/d</td>
<td>Drowsiness, dizziness, blurred vision, ataxia, headache, nausea, rash</td>
<td>Drug of first choice for idiopathic trigeminal neuralgia; as an enzyme inducer, it might interfere with activity of other drugs such as warfarin; monitoring of blood counts and liver function recommended</td>
</tr>
<tr>
<td><strong>TCAs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Amitriptyline, nortriptyline, or desipramine</td>
<td>10–25 mg/d</td>
<td>Increase by 10 mg/d every wk</td>
<td>10–100 mg/d</td>
<td>Drowsiness, confusion, orthostatic hypotension, dry mouth, constipation, urinary retention, weight gain, arrhythmia</td>
<td>Amitriptyline more likely to produce drowsiness and anticholinergic side effects; contraindicated in patients with glaucoma, symptomatic prostatism, and substantial cardiovascular disease</td>
</tr>
<tr>
<td><strong>SNRIs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Venlafaxine</td>
<td>37.5 mg/d</td>
<td>Increase by 37.5 mg/d every wk</td>
<td>150–225 mg/d</td>
<td>Nausea, dizziness, drowsiness, hyperhidrosis, hypertension</td>
<td>Dosage adjustments required in renal failure</td>
</tr>
<tr>
<td>• Duloxetine</td>
<td>30 mg/d</td>
<td>Increase by 30 mg/d every wk</td>
<td>60–120 mg/d</td>
<td>Sedation, nausea, constipation, ataxia, dry mouth</td>
<td>Contraindicated in patients with glaucoma</td>
</tr>
<tr>
<td><strong>Controlled-release opioids</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Oxycodone</td>
<td>10 mg every 12 h</td>
<td>NA</td>
<td>NA</td>
<td>Nausea, vomiting, sedation, dizziness, urinary retention, constipation</td>
<td>Constipation requires concurrent bowel regimen; monitor for overdose, effectiveness, tolerance, dependence, and appropriateness</td>
</tr>
<tr>
<td>• Hydromorphone</td>
<td>3 mg every 12 h</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Tramadol</td>
<td>50 mg/d</td>
<td>Increase by 50 mg/d every wk</td>
<td>50–100 mg 4 times/d or 100–400 mg/d (controlled release)</td>
<td>Ataxia, sedation, constipation, seizures, orthostatic hypertension</td>
<td>Might lower seizure threshold; use with caution in patients with epilepsy</td>
</tr>
<tr>
<td>• Tapentadol (controlled release)</td>
<td>50 mg every 12 h</td>
<td>Increase by 50 mg/dose every wk</td>
<td>Maximum dose 500 mg in 24 h</td>
<td>Nausea, constipation, somnolence, dizziness, vomiting, fatigue</td>
<td>Contraindicated in patients with creatinine clearance &lt; 0.5 mL/s/m² and Child–Pugh class C. Caution in those at risk of seizure</td>
</tr>
<tr>
<td>• Lidocaine</td>
<td>NA</td>
<td>NA</td>
<td>5% patches or gel applied to painful areas for 12 h in a 24-h period</td>
<td>NA</td>
<td>Most useful for postherpetic neuralgia; has virtually no systemic side effects; lidocaine patches not available in Canada</td>
</tr>
<tr>
<td>• THC or nabiximols</td>
<td>1–2 sprays every 4 h, maximum 4 sprays on day 1</td>
<td>NA</td>
<td>2 sprays 4 times/d</td>
<td>Dizziness, fatigue, nausea, euphoria</td>
<td>Approved in Canada for neuropathic pain associated with multiple sclerosis; causes positive urine drug test results for cannabinoids; monitor application site (oral mucosa)</td>
</tr>
<tr>
<td>• Nabilone</td>
<td>0.25–0.5 mg at night (owing to side effects of drowsiness and fatigue)</td>
<td>Increase by 0.5 mg/d every wk</td>
<td>3 mg twice daily</td>
<td>Dizziness, drowsiness, dry mouth</td>
<td>Approved in Canada for nausea and vomiting associated with chemotherapy. Does not cause positive test results for cannabinoids on routine urine drug testing</td>
</tr>
</tbody>
</table>

NA—not available, SNRI—serotonin-norepinephrine reuptake inhibitor, TCA—tricyclic antidepressant, THC—tetrahydrocannabinol.

*Opioid initial dosing recommendations are for healthy opioid-naïve adults; opioid titration and dose range are not included owing to variability of patient and pain factors.

Adapted with permission from Moulin et al.7
However, once opioid medications are entrenched, the effect sizes of these first-line medications tend to be minimized.

**Second-line analgesics.** Tramadol is a second-line medication in the treatment of NeP and has been shown to be of benefit in RCTs for diabetic neuropathy and mixed NeP syndromes. It is a weak μ-opioid receptor agonist and weak SNRI. The NeuPSIG also recommends it as a second-line agent. Tramadol might cause less constipation and nausea compared with other weak analgesics. Along with common opioid side effects, tramadol can decrease seizure thresholds and can increase the risk of serotonin syndrome when combined with other serotonergic drugs.

Opioids were found to be more effective than placebo for pain, with a moderate effect size, in a meta-analysis including 16 randomized trials for chronic NeP. However, owing to their potential adverse effects, medical complications (endocrine dysfunction, sleep apnea, opioid-induced hyperalgesia), risks (overdose, diversion, addiction, withdrawal), and necessity of more specialized follow-up and monitoring, opioids are considered to be second-line agents for NeP (Table 3). In the recent NeuPSIG systematic review and meta-analysis, opioids are recommended as third-line analgesics for the same reasons.

A meta-analysis of 62 RCTs found that the most common opioid-related adverse effects were nausea (28%), constipation (25%), drowsiness (24%), dizziness (18%), and vomiting (15%). Although some tolerance to side effects develops, there is little tolerance to constipation in prolonged use. Long-term opioid use complications include opioid-induced hyperalgesia and multiple endocrine axis suppression such as adrenal and gonadal suppression. The 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain is strongly recommended as a resource for family physicians. An online and mobile resource, My Opioid Manager, is recommended to help inform and engage patients to work with their health care providers in managing their pain with opioids. Another mobile app, Manage My Pain, has more than 25,000 active users and is used in chronic pain to empower the physician-patient relationship.

**Third-line analgesics.** Cannabinoids have been moved from a fourth-line to a third-line treatment option for chronic NeP in the 2014 CPS NeP guidelines. The strongest evidence for cannabinoid use is for NeP from HIV, diabetic neuropathy, posttraumatic or postsurgical NeP, and mixed central and peripheral NeP states. However, there is a paucity of high-quality studies with long trial duration, large sample size, and large effect size to better establish their efficacy and their potential for abuse. The NeuPSIG provides a weak recommendation against the use of cannabinoids in NeP owing to potential for misuse, diversion, and long-term risks in susceptible individuals. Side effects of cannabinoids can vary but usually include somnolence, “getting high,” confusion, dizziness, tachycardia, and hypotension.

Cannabinoid formulations in Canada currently consist of nabilone, nabiximols, and dried cannabis. Dosing for dried cannabis is highly individualized and relies greatly on titration owing to complex pharmacology, interindividual genetic differences in cannabinoid receptors, metabolism, and previous exposure. In clinical trials with positive results using dried cannabis for NeP conditions, the delta-9-tetrahydrocannabinol dose per day did not exceed 125 mg, and maximum tetrahydrocannabinol by weight was 9.4%. Although there is no established dosing guideline for dried cannabis, the Health Canada monograph on cannabis provides “rough” dosing guidelines. Dried cannabis is not approved or regulated by Health Canada because it has not gone through the necessary rigorous scientific trials for efficacy or safety. Provincial guides and policies on medical marijuana can be found on the Canadian Medical Protective Association website. For family physicians starting, maintaining, or terminating dried cannabis prescriptions, preliminary guidelines have been created by the College of Family Physicians of Canada.

As per current guidelines, cannabis is not appropriate to start in those who are younger than 25 years of age, might be pregnant, have cardiovascular disease, have a respiratory disease, have a history of psychosis, or have a substance use disorder. In patients naïve to cannabis, a trial with a synthetic cannabinoid, usually nabilone, should be considered first. If dried cannabis is prescribed, physicians must continue to follow up and monitor patients to assess for potential misuse, abuse, and efficacy. Discontinuation of cannabis therapy is warranted when there is clearly no benefit or it is causing harm to the patient. It is important also to be cognizant of cannabis hyperemesis syndrome as a differential diagnosis in young patients who present with cyclic vomiting and compulsive hot bathing. There are several large-scale Canadian initiatives under way with the aim of creating evidence-based recommendations on the prescription of medical cannabis.

**Fourth-line analgesics.** Selective serotonin reuptake inhibitors are another class of antidepressants that have some analgesic efficacy, with the exception of fluoxetine, in painful diabetic neuropathy and painful polyneuropathy. Similar to SNRIs, there is a risk of serotonin syndrome with medications that increase serotonin levels and they are also contraindicated in combination with monoamine oxidase inhibitors.

Topical lidocaine is a local anesthetic useful in the management of peripheral NeP. It remains a second-line agent specifically for postherpetic neuralgia.
However, there was no benefit shown in postsurgical nerve injury or in mixed NeP.65,66 Topical lidocaine is safe, as only negligible levels are detected in blood and there are rarely any systemic side effects with topical use.67

Capsaicin is another topical agent with evidence for effectiveness at high concentrations (8%) in postherpetic neuralgia and in painful HIV neuropathy for up to 12 weeks after a single application.68 As initial application of capsaicin causes sensitivity of nociceptors leading to an intense burning sensation, local anesthetic before application might be required. In Canada, the high-potency capsaicin patch may be obtained through compassionate release.

<table>
<thead>
<tr>
<th>Table 3. Selected opioid safety considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OPIOID</strong></td>
</tr>
<tr>
<td>Codeine</td>
</tr>
<tr>
<td>Tramadol</td>
</tr>
<tr>
<td>Morphine</td>
</tr>
<tr>
<td>Oxycodone, hydromorphone, hydrocodone</td>
</tr>
</tbody>
</table>
| Fentanyl | • Before starting fentanyl, ensure the patient has been fully opioid tolerant during the previous 2 wk (total dose of at least 60-90 mg/d morphine equivalence) on a scheduled dose (at least twice daily for CR or 4 times daily for IR)  
• Do not switch from codeine to fentanyl regardless of the codeine dose, as some patients taking codeine might have little or no opioid tolerance  
• Maintain the starting dose for at least 6 d and use extra caution with patients at higher risk of overdose (eg, the elderly, those taking benzodiazepines)  
• Advise the patient as follows:  
  - Be alert for signs of overdose; if detected, remove the patch and seek medical attention  
  - Apply the patches as prescribed; do not apply more than 1 patch at a time  
  - Avoid heat sources such as heating pads  
  - Enforce patch-for-patch exchange at pharmacy to reduce diversion |
| Methadone | • Use methadone to treat pain only if you hold a written Health Canada exemption  
• Titration is hazardous because of its very long half-life, which leads to bioaccumulation |
| Meperidine | • Not recommended for use in CNCP owing to poor bioavailability and inferior effectiveness to codeine  
• Normeperidine, a metabolite of meperidine, can accumulate with frequent use causing seizures and delirium |
| Acetaminophen-opioid combinations | • Use with caution to not exceed maximum dose of 3.2 g/d of acetaminophen for adults (10 tablets/d of opioid-acetaminophen combinations)  
• No more than 8 tablets/d for tramadol-acetaminophen combinations  
• Warn alcohol drinkers to not mix alcohol with acetaminophen |
| CR formulations | • Each CR tablet can contain a higher opioid dose than IR formulations do and can be converted to IR by biting or crushing the tablet |
| Tapentadol | • Contraindicated in those with severe hepatic or renal dysfunction, or taking monoamine oxidase inhibitors  
• Small risk of seizure seen in postmarketing reports |
| Parenteral opioids | • Parenteral opioids are not recommended for treatment of CNCP owing to increased risk of overdose, abuse, addiction, and infection |

Adapted with permission from the Michael G. DeGroote National Pain Centre.46

Methadone is a synthetic opioid with unique N-methyl-D-aspartate and SNRI properties.69 Only small RCTs and surveys have suggested efficacy in mixed NeP conditions.70-72 In Canada, a specialized methadone exemption is required for prescribing and guidelines are available for its management in chronic pain.73 Tapentadol is a newer opioid available in Canada with analgesic effect through µ-receptors and monoamine reuptake inhibition, but minimal effect on serotonin reuptake. This dual analgesic effect might contribute to its efficacy in treating painful diabetic neuropathy.74 Like other opioids, common side effects include nausea and vomiting, somnolence, and dizziness but with lower incidence
compared with oxycodone. Another advantage is the lower potential for metabolic variation due to enzyme polymorphism. Similar to tramadol, serotonin syndrome can occur when combined with other serotonergic drugs but at a reduced rate.\(^7\) As the efficacy of tapentadol has only been studied in a single NP pain model, it is considered a fourth-line agent and is not included as a second-line treatment with tramadol and other opioids.

Other anticonvulsants studied in NP management include lamotrigine, lacosamide, topiramate, and valproic acid. Lamotrigine provided negative results in studies of diabetic neuropathy, mixed NP, chemotherapy-induced NP, and spinal cord injury pain. Results of small studies investigating lamotrigine’s effect in HIV neuropathy, trigeminal neuralgia, and central poststroke pain were positive.\(^7\) Lacosamide has been mostly studied in the context of painful diabetic neuropathy with modest benefit.\(^7\) Topiramate and valproic acid have had mixed results in NP trials.\(^18\)

Botulinum toxin injections represent a novel treatment in NP with positive results in diabetic neuropathy and focal painful neuropathy. However, these studies are underpowered, with small sample sizes.\(^78,79\) Therefore, the evidence for botulinum toxin remains preliminary and further evidence is needed.

**Combination pharmacotherapy.** Recent review of combination pharmacotherapy in the treatment of NP has involved variations of an opioid with gabapentin, pregabalin, or a TCA, the combination of gabapentin and nortriptiline, and various topical medications.\(^80\) A meta-analysis of the combination of gabapentin with an opioid showed superiority in terms of analgesia when compared with gabapentin alone, but the combination also led to more discontinuations owing to side effects.\(^80\) An RCT comparing duloxetine (60 mg daily) and pregabalin (300 mg daily) to high-dose duloxetine or pregabalin monotherapy did not yield any difference in 24-hour pain; however, all secondary outcome measures favoured combination therapy.\(^81\) Current evidence does not support a recommendation of any one specific drug combination for NP, but it remains an important and understudied strategy.

**Conclusion**

Based on the 2014 CPS NP consensus statement,\(^7\) gabapentinoids and TCAs continue to play an important role for first-line management of NP. As a result of evidence published since the 2007 CPS NP consensus statement, SNRIs are now also among the first-line agents. Topical lidocaine, a previous second-line agent, remains in the same tier of treatment only for postherpetic neuralgia, but is otherwise now a fourth-line agent. Opioids including tramadol have been moved from third-line to second-line treatment. Cannabinoids (including dried cannabis) have been elevated from fourth-line agents to a third-line treatment option for chronic NP. The fourth-line analgesic medications are understood but can still be of therapeutic value when other options have failed or are intolerable.

Dr Mu is an anesthesiologist in the Pain Research Unit in the Department of Anesthesia at the Toronto General Hospital in Ontario. Dr Weinberg is a general practitioner practising in Toronto. Dr Moulin is Professor in the Department of Clinical Neurological Sciences and the Department of Oncology at Western University in London, Ont. Dr Clarke is Assistant Professor in the Department of Anesthesia and in the Transitional Pain Service of the Toronto General Hospital at the University of Toronto.

**Contributors**

All authors contributed to the literature review and interpretation, and to preparing the manuscript for submission.

**Competing Interests**

None declared

**Correspondence**

Dr Alex Mu, e-mail alexmu182@gmail.com

**References**
